Results from a three-year follow-up of venetoclax in patients with R/R AL amyloidosis 

Rahel Schwotzer, MD, University Hospital Zürich, Zürich, Switzerland, discusses the findings from a three-year follow-up of venetoclax in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Of the nine high-risk patients in the initial cohort, two had a very good partial response (VGPR) and seven had a complete response (CR) to venetoclax. Additionally, all patients were still alive at the three-year follow up, which is very promising. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.